TSAO-T

目录号: HY-15354 一键复制产品信息: Data Sheet 产品使用指南
FAQs
技术支持

TSAO-T 是一种 HIV-1 逆转录酶抑制剂。TSAO-T 可用于 HIV 感染的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

TSAO-T Chemical Structure

CAS No. : 141781-17-1

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格		是否有货
50 mg		询价
100 mg		询价
250 mg		询价

or 大包装询价

* Please select Quantity before adding items.

TSAO-T 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

查看所有亚型

HIV HIV-1 HIV-2

生物活性
纯度 & 产品资料
参考文献

生物活性

TSAO-T is a HIV-1 reverse transcriptase inhibitor. TSAO-T can be used in the research of HIV infection^[1].

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	12 μM Compound: TSAO-T	Cytotoxicity against human CEM cells after 4 days Cytotoxicity against human CEM cells after 4 days	[PMID: 21880398]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected CEM cell cultures	[PMID: 15974581]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days Cytotoxicity against mock-infected human CEM cells assessed as reduction of cell viability after 4 days	[PMID: 18316194]
CCRF-CEM	CC₅₀	16 μM Compound: TSAO-T	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.01 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138D mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.03 μg/mL Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 3B infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV1 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B in CEM cells assessed as inhibition of viral replication	[PMID: 18353641]
CCRF-CEM	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV1 3B infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	0.07 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase L100I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.22 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V179N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.23 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase K103N mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	0.4 μM Compound: TSAO-T	Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Lys103-Asn mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	1.9 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase V106A mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	2 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181C mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	3 μM Compound: TSAO-T	Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Tyr181- Cys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	4.6 μM Compound: TSAO-T	Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50% Concentration of compound inhibiting Glu138-Lys mutant HIV-1(IIIB) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase G190E mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y181I mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 10 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188L mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 20 μM Compound: 7, TSAO-T	Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against wild type HIV2 infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 20 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days Antiviral activity against HIV2 ROD infected in human CEM cells assessed as inhibition of virus-induced cytopathicity after 4 days	[PMID: 21880398]
CCRF-CEM	EC₅₀	> 3.3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase Y188H mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 3 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase E138K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
CCRF-CEM	EC₅₀	> 4 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in CEM cell culture by 50%	[PMID: 15974581]
CCRF-CEM	EC₅₀	> 4 μM Compound: TSAO-T	Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HIV2 ROD in CEM cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 18316194]
CCRF-CEM	EC₅₀	> 50 μg/mL Compound: 7, TSAO-T	Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation Antiviral activity against HIV1 3B harboring reverse transcriptase N136A/Q/K mutant infected in human CEM cells assessed as inhibition of syncytia formation	[PMID: 21446702]
Huh-7	CC₅₀	> 100 μM Compound: TSAO-T	Cytotoxicity against human HuH7 cells after 72 hrs Cytotoxicity against human HuH7 cells after 72 hrs	[PMID: 21880398]
Huh-7	EC₅₀	14 μM Compound: TSAO-T	Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay Antiviral activity against HCV2a JFH1 infected in human Huh7 cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	[PMID: 21880398]
Lymphocyte	EC₅₀	0.034 μg/mL Compound: 12a	Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells. Concentration required to inhibit HIV-1 induced cytopathicity in human MT-4 lymphocyte cells.	[PMID: 1495006]
MT4	CC₅₀	14 μM Compound: TSAO-T	Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures Concentration of compound required to reduce by 50% the number of viable cells in mock infected MT-4 cell cultures	[PMID: 15974581]
MT4	CC₅₀	14 μM Compound: TSAO-T	Inhibition of MT4 cell viability Inhibition of MT4 cell viability	[PMID: 16884295]
MT4	CC₅₀	7.7 μg/mL Compound: 12a	Concentration required to reduce human MT-4 cell viability by 50%. Concentration required to reduce human MT-4 cell viability by 50%.	[PMID: 1495006]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-1(IIIB) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]
MT4	EC₅₀	0.06 μM Compound: TSAO-T	Antiviral activity against HIV1 in MT4 cells Antiviral activity against HIV1 in MT4 cells	[PMID: 16884295]
MT4	EC₅₀	> 20 μM Compound: TSAO-T	Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50% Concentration of compound required to inhibit HIV-2 (ROD) induced cytopathicity in MT-4 cell culture by 50%	[PMID: 15974581]

分子量

589.85

Formula

C₂₄H₄₃N₃O₈SSi₂

CAS 号

141781-17-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料

产品使用指南 (1538 KB)

参考文献

[1]. Bonache MC, et al. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem. 2005 Oct 20;48(21):6653-60. [Content Brief]

TSAO-T 相关分类

Infection

摩尔计算器
稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量		浓度		体积		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)	×	体积 _(start)	=	浓度 _(final)	×	体积 _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TSAO-T141781-17-1Reverse TranscriptaseHIVHuman immunodeficiency virusHIV-1HIV-2Inhibitorinhibitorinhibit

您最近查看的产品:

产品名称：

* 需求量：

* 客户姓名：

* Email：

* 电话：

* 公司或机构名称：

留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
粤ICP备2021105330号-3 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2026 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

粤ICP备2021105330号-3

上海工商

沪公网安备31011502019417

沪(浦)应急管危经许[2021]201709(QFYS)

营业执照（三证合一）

TSAO-T

TSAO-T 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

TSAO-T 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

TSAO-T

TSAO-T 相关抗体

TSAO-T 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 HIV 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

TSAO-T 相关分类

摩尔计算器

稀释计算器

The molarity calculator equation

The dilution calculator equation

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z